A drug to treat advanced prostate cancer should be given to patients on the NHS, a health watchdog has said.
Abirateron, marketed as Zytiga, can extend the lives of late-stage cancer sufferers by more than three months.
The National Institute for Health and Clinical Excellence (Nice) revised its recommendations after fresh information from manufacturer Janssen, and the new draft guidance was welcomed by experts.
More top news
Freezing, frosty and icy again tonight as temperatures fall.
Fashion giant Michael Kors Holdings announces that it is phasing out real fur over the next year.
The little boy cried for help but began making the two-mile journey home on his own when there was no response.